UroGen Pharma Ltd. Balance Sheet
URGN / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 10 fiscal years. All figures from audited SEC 10-K filings.
UroGen Pharma Ltd. had $200M in total assets with negative shareholders' equity of $105M as of FY2025. Total debt was $125M against $111M in cash, resulting in $14M net debt.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110.7M | $172.0M | $95.0M | $55.4M | $44.4M | $52.9M | $49.7M | $101.3M | $37.0M | - |
| Accounts Receivable | $33.1M | $20.3M | $15.4M | $12.7M | $11.7M | $7.0M | - | - | - | - |
| Inventory | $16.5M | $9.2M | $5.7M | $4.3M | $4.8M | $2.0M | - | - | $316.0K | - |
| Current Assets | $186.0M | $276.1M | $169.2M | $128.9M | $114.4M | $115.6M | $148.6M | $102.2M | $74.5M | - |
| PP&E (Net) | $637.0K | $655.0K | $689.0K | $1.3M | $2.0M | $2.0M | $977.0K | $948.0K | $805.0K | - |
| Total Assets | $200.5M | $285.7M | $178.3M | $135.6M | $119.7M | $122.0M | $202.4M | $103.6M | $75.5M | - |
| Current Liabilities | $46.4M | $45.9M | $31.2M | $23.9M | $22.4M | $21.4M | $19.5M | $13.5M | $7.0M | - |
| Total Debt | $125.0M | $121.7M | $98.6M | $97.5M | $0 | - | - | - | - | - |
| Shareholders' Equity | -$105.5M | -$65.2M | -$89.4M | $8.4M | $8.4M | $180.3M | $90.1M | $90.1M | $68.5M | $16.3M |